Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says

Reuters2021-03-12

By Michael Erman

NEW YORK, March 11 (Reuters) - Pfizer Inc and BioNTech SE will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.

"We will exceed clearly, this year, the 2 billion doses," Bourla said in an interview.

By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.

Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.

"Those have already been manufactured" and are currently being tested for quality, he said.

"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail," he said.

(Reporting by Michael Erman Editing by Bill Berkrot)

((michael.erman@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2118933190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-03-12 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2118933190","market":"us","top_or_hot":-1,"title":"Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says","media":"Reuters","content":"<html><body><p>By Michael Erman</p><p>   NEW YORK, March 11 (Reuters) - Pfizer Inc    and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.</p><p>   \"We will exceed clearly, this year, the 2 billion doses,\" Bourla said in an interview.</p><p>   By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.</p><p>   Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.</p><p>   \"Those have already been manufactured\" and are currently being tested for quality, he said. </p><p>   \"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail,\" he said.        </p><p> (Reporting by Michael Erman Editing by Bill Berkrot)</p><p>((michael.erman@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to exceed 2021 vaccine production target by as much as 20%, CEO says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-12 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Michael Erman   NEW YORK, March 11 (Reuters) - Pfizer Inc    and BioNTech SE    will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2118933190","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2118933190","pubTimestamp":1615482033,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"By Michael Erman   NEW YORK, March 11 (Reuters) - Pfizer Inc    and BioNTech SE    will exceed their","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"首席执行官称辉瑞将比2021年疫苗产量目标高出20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"By Michael Erman   NEW YORK, March 11 (Reuters) - Pfizer Inc    and BioNTech SE    will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.   \"We will exceed clearly, this year, the 2 billion doses,\" Bourla said in an interview.   By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.   Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.   \"Those have already been manufactured\" and are currently being tested for quality, he said.    \"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail,\" he said.         (Reporting by Michael Erman Editing by Bill Berkrot)((michael.erman@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2118933190"}